IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Impax Laboratories Inc. (“Impax” or the “Company”) (Nasdaq: IPXL) concerning possible violations of federal securities laws.
If you purchased shares of Impax and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
The investigation focuses on whether Impax and certain of its officers and/or directors violated federal securities laws. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Impax, to determine whether they unlawfully colluded with each other to fix generic drug prices. When this information was announced, shares of Impax declined in value.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.